Cover Image
市場調查報告書

靜脈注射(IV)用溶液市場分析:各類型(完全靜脈營養,末梢靜脈營養),營養素別(碳水化合物,非口服脂肪乳劑,單劑量氨基酸溶液,維生素和礦物質),及市場區隔預測

Intravenous (IV) Solutions Market Analysis by Type (Total Parenteral Nutrition, Peripheral Parenteral Nutrition), Nutrients (Carbohydrates, Parenteral Lipid Emulsion, Single Dose Amino Acid Solution, Vitamins & Minerals) And Segment Forecasts to 2024

出版商 Grand View Research, Inc. 商品編碼 374607
出版日期 內容資訊 英文 65 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
靜脈注射(IV)用溶液市場分析:各類型(完全靜脈營養,末梢靜脈營養),營養素別(碳水化合物,非口服脂肪乳劑,單劑量氨基酸溶液,維生素和礦物質),及市場區隔預測 Intravenous (IV) Solutions Market Analysis by Type (Total Parenteral Nutrition, Peripheral Parenteral Nutrition), Nutrients (Carbohydrates, Parenteral Lipid Emulsion, Single Dose Amino Acid Solution, Vitamins & Minerals) And Segment Forecasts to 2024
出版日期: 2016年10月03日 內容資訊: 英文 65 Pages
簡介

本報告提供全球靜脈注射(IV)用溶液市場相關調查,市場概要和今後預測,彙整各市場區隔及地區別趨勢,及加入此市場的主要企業簡介等資料。

第1章 調查方法與範圍

第2章 摘要整理

第3章 IV溶液產業預測

  • 市場區隔
  • 市場規模與成長預測
  • 市場趨勢
    • 推動市場的要素分析
    • 阻礙市場的要素分析
  • 優先的機會
  • 主要企業的市場佔有率
  • 競爭分析
  • 產業分析:波特五力分析
  • PESTEL分析
  • 產品技術/研究

第4章 市場類別1:各類型預測與趨勢分析

  • IV溶液市場:各類型趨勢分析
  • 完全靜脈營養
  • 末梢靜脈營養

第5章 市場類別2:營養素別預測與趨勢分析

  • IV溶液市場:營養素別趨勢分析
  • 碳水化合物
  • 單劑量氨基酸溶液
  • 維生素和礦物質
  • 非口服脂肪乳劑
  • 其他

第6章 市場類別3:各地區預測及趨勢分析

  • 各地區市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第7章 競爭環境

目錄
Product Code: GVR-1-68038-137-5

The global IV solutions market was valued at USD 6.9 billion in 2015 and is expected to reach a value of USD 13.79 billion by 2024. Key factors driving market expansion include the rapidly increasing natality rate including a high percentage of premature births and malnutrition.

Growing incidence rate of chronic diseases, such as cancer, is also fueling the demand for Total Parenteral Nutrition (TPN), which forms a vital part of the treatment. Intravenous nutrition helps sustain strength, maintains hydration levels in patients, and facilitates faster recovery. Cancer prevalence is forecasted to grow by 70% over the next few decades. This poses a colossal growth prospect for the market.

The regulatory bodies are approving high-quality products complying with faster patient recovery. In May 2016, Amanta Healthcare received approval for NaCl injection BP and Sterile water injection BP products. These products obtained Therapeutic Goods Administration approval granted by the Australian government.

The reimbursement scenario for IV nutrition is promising. In the U.S., Medicare covers up to 80% of the expenses of parenteral and enteral nutrition including physician services, medical equipment, and other related medical services. In the developing countries, increasing purchasing power compensates for the absence of reimbursement coverage thus sustaining the growth of this vertical.

Further Key Findings From the Study Suggest:

TPN dominated the market in 2015. TPN is administered to patients who are 'nil by mouth' or are afflicted with dysfunctional digestive systems. Around 2000 elderly deaths occur per annum due to malnutrition. With rising geriatric population and chronic, but manageable diseases, the demand for TPN is projected to grow over the forecast period.

In 2015, North America dominated the market with a revenue share of around 40%. The region has a large geriatric population base comprising 45% long-term care residents and 40% hospitalized, elderly patients suffering from malnutrition. Moreover, in 2014, the region experienced a sharp shortage of IV fluids due to increased hospitalization of influenza patients. In response to the deficit, FDA initiatives were directed toward expediting the application review process and identifying potential new manufacturers.

Asia Pacific is expected to emerge as the fastest growing region. The rising geriatric population in Japan and China, increasing tendencies of unhealthy food consumption, and low level of awareness is expected to promote the emergence of IV solutions market in this region.

Fresenius Kabi AG, Baxter, B. Braun Melsungen AG, and Hospira are few players operating in the market. Mergers and acquisitions are certain strategic initiatives undertaken by the companies. For instance, Claris-Otsuka is a joint venture between Claris Lifesciences Ltd., Otsuka Pharmaceutical Co., Ltd., and Mitsui & Co., Ltd., Japan established in 2012. This joint venture focused on the manufacturing and marketing activities for IV nutrition products and offers products in various IV delivery systems.

Table of Content

Chapter 1: Research Methodology

  • 1.1. Information Procurement

Chapter 2: Executive Summary

Chapter 3: IV Solutions Industry Outlook

  • 3.1. Market Segmentation
  • 3.2. Market Size and Growth Prospects, 2013-2024
  • 3.3. IV Solutions Market Dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Increasing natality rate
      • 3.3.1.2. Rising number of premature births
      • 3.3.1.3. Risk of malnutrition
      • 3.3.1.4. Rising geriatric population base
      • 3.3.1.5. Increasing incidence of cancer
    • 3.3.2. Market restraint analysis
      • 3.3.2.1. Shortage of parenteral nutrition products
      • 3.3.2.2. Increased use of enteral nutrition
      • 3.3.2.3. High risk of infection
      • 3.3.2.4. Stringent regulations
  • 3.4. Key Opportunities Prioritized
  • 3.5. Clinical nutrition market: 2014(E) percentage market share of major companies
  • 3.6. Intravenous solution products market: 2013 percentage market share of major companies
  • 3.7. Competition analysis(Strategic Initiatives)
  • 3.8. Industry Analysis-Porter's
  • 3.9. IV Solutions PESTEL Analysis
  • 3.10. Product technology/Research

Chapter 4: Market Categorization 1: Type Estimates & Trend Analysis

  • 4.1. Global IV Solutions Market: Type Movement Analysis
  • 4.2. Total Parenteral Nutrition Market(TPN)
    • 4.2.1. Total Parenteral Nutrition Market(TPN) market estimates and forecasts, 2013-2024(USD Million)
  • 4.3. Peripheral Parenteral Nutrition(PPN)
    • 4.3.1. Peripheral Parenteral Nutrition(PPN) market estimates and forecasts, 2013-2024(USD Million)

Chapter 5: Market Categorization 2: Nutrient Estimates & Trend Analysis

  • 5.1. Nutrient Movement Analysis & Market Share, 2015 & 2024
  • 5.2. Carbohydrates
    • 5.2.1. Carbohydrates market estimates and forecasts, 2013-2024(USD Million)
  • 5.3. Single dose amino acid solution
    • 5.3.1. Single dose amino acid solution market estimates and forecasts, 2013-2024(USD Million)
  • 5.4. Vitamins & minerals(salt and electrolyte)
    • 5.4.1. Vitamins & minerals(salt and electrolyte) market estimates and forecasts, 2013-2024(USD Million)
  • 5.5. Parenteral lipid emulsion
    • 5.5.1. Parenteral lipid emulsion market estimates and forecasts, 2013-2024(USD Million)
  • 5.6. Others(trace elements)
    • 5.6.1. Others(trace elements) market estimates and forecasts, 2013-2024(USD Million)

Chapter 6: Market Categorization 3: Regional Estimates & Trend Analysis, by Type & Nutrient

  • 6.1. Regional Movement Analysis & Market Share, 2015 & 2024
  • 6.2. North America
    • 6.2.1. North America IV solutions market, by type, 2013-2024(USD Million)
    • 6.2.2. North America IV solutions market, by nutrient, 2013-2024(USD Million)
    • 6.2.3. U.S.
      • 6.2.3.1. U.S. IV solutions market, by type, 2013-2024(USD Million)
      • 6.2.3.2. U.S. IV solutions market, by nutrient, 2013-2024(USD Million)
    • 6.2.4. Canada
      • 6.2.4.1. Canada IV solutions market, by type, 2013-2024(USD Million)
      • 6.2.4.2. Canada IV solutions market, by nutrient, 2013-2024(USD Million)
  • 6.3. Europe
    • 6.3.1. Europe IV solutions market, by type, 2013-2024(USD Million)
    • 6.3.2. Europe IV solutions market, by nutrient, 2013-2024(USD Million
    • 6.3.3. Germany
      • 6.3.3.1. Germany IV solutions market, by type, 2013-2024(USD Million)
      • 6.3.3.2. Germany IV solutions market, by nutrient, 2013-2024(USD Million)
    • 6.3.4. UK
      • 6.3.4.1. UK IV solutions market, by type, 2013-2024(USD Million)
      • 6.3.4.2. UK IV solutions market, by nutrient, 2013-2024(USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific IV Solutions market, by type, 2013-2024(USD Million)
    • 6.4.2. Asia Pacific IV Solutions market, by nutrient, 2013-2024(USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Japan IV Solutions market, by type, 2013-2024(USD Million)
      • 6.4.3.2. Japan IV Solutions market, by nutrient, 2013-2024(USD Million)
    • 6.4.4. China
      • 6.4.4.1. China IV Solutions market, by type, 2013-2024(USD Million)
      • 6.4.4.2. China IV Solutions market, by nutrient, 2013-2024(USD Million)
    • 6.4.5. India
      • 6.4.5.1. India IV Solutions market, by type, 2013-2024(USD Million)
      • 6.4.5.2. India IV Solutions market, by nutrient, 2013-2024(USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Australia IV Solutions market, by type, 2013-2024(USD Million)
      • 6.4.6.2. Australia IV Solutions market, by nutrient, 2013-2024(USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America IV Solutions market, by type, 2013-2024(USD Million)
    • 6.5.2. Latin America IV Solutions market, by nutrient, 2013-2024(USD Million)
    • 6.5.3. Brazil
      • 6.5.3.1. Brazil IV Solutions market, by type, 2013-2024(USD Million)
      • 6.5.3.2. Brazil IV Solutions market, by nutrient, 2013-2024(USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Mexico IV Solutions market, by type, 2013-2024(USD Million)
      • 6.5.4.2. Mexico IV Solutions market, by nutrient, 2013-2024(USD Million)
  • 6.6. MEA
    • 6.6.1. MEA IV Solutions market, by type, 2013-2024(USD Million)
    • 6.6.2. MEA IV Solutions market, by nutrient, 2013-2024(USD Million)
    • 6.6.3. South Africa
      • 6.6.3.1. South Africa IV Solutions market, by type, 2013-2024(USD Million)
      • 6.6.3.2. South Africa IV Solutions market, by nutrient, 2013-2024(USD Million)

Chapter 7: Competitive Landscape

  • 7.1. Fresenius Kabi
    • 7.1.1. Company overview
    • 7.1.2. Financial performance
    • 7.1.3. Product benchmarking
    • 7.1.4. Strategic initiatives
  • 7.2. Sino-Swed Pharmaceutical Corp., Ltd.
    • 7.2.1. Company overview
    • 7.2.2. Financial performance
    • 7.2.3. Product benchmarking
    • 7.2.4. Strategic initiatives
  • 7.3. Hospira
    • 7.3.1. Company overview
    • 7.3.2. Financial performance
    • 7.3.3. Product benchmarking
    • 7.3.4. Strategic initiatives
  • 7.4. Amanta Healthcare
    • 7.4.1. Company overview
    • 7.4.2. Financial performance
    • 7.4.3. Product benchmarking
    • 7.4.4. Strategic initiatives
  • 7.5. Otsuka Pharmaceutical Co., Ltd.
    • 7.5.1. Company overview
    • 7.5.2. Financial performance
    • 7.5.3. Product benchmarking
    • 7.5.4. Strategic initiatives
  • 7.6. Sichuan Kelun Pharmaceutical Co., Ltd.
    • 7.6.1. Company overview
    • 7.6.2. Financial performance
    • 7.6.3. Product benchmarking
    • 7.6.4. Strategic Initiatives
  • 7.7. Terumo Corporation
    • 7.7.1. Company overview
    • 7.7.2. Financial performance
    • 7.7.3. Product benchmarking
    • 7.7.4. Strategic initiatives
  • 7.8. Baxter
    • 7.8.1. Company overview
    • 7.8.2. Financial performance
    • 7.8.3. Product benchmarking
    • 7.8.4. Strategic initiatives
  • 7.9. B. Braun Melsungen AG
    • 7.9.1. Company overview
    • 7.9.2. Financial performance
    • 7.9.3. Product benchmarking
    • 7.9.4. Strategic initiatives
  • 7.10. Claris Lifesciences Ltd.
    • 7.10.1. Company overview
    • 7.10.2. Financial performance
    • 7.10.3. Product benchmarking
    • 7.10.4. Strategic initiatives
  • 7.11. Kyowa Hakko Bio Co., Ltd.
    • 7.11.1. Company overview
    • 7.11.2. Financial performance
    • 7.11.3. Product benchmarking
    • 7.11.4. Strategic initiatives
  • 7.12. Grifols
    • 7.12.1. Company overview
    • 7.12.2. Financial performance
    • 7.12.3. Product benchmarking
    • 7.12.4. Strategic initiatives
  • 7.13. Liqvor Pharmaceuticals
    • 7.13.1. Company overview
    • 7.13.2. Financial performance
    • 7.13.3. Product benchmarking
    • 7.13.4. Strategic initiatives

List of Tables

  • TABLE 1: Intravenous solutions - global market current and forecast by regions (2015 - 2024) in (USD Million)
  • TABLE 2: North America IV solutions market estimates and forecasts, by region, 2013 - 2024 (USD Million)
  • TABLE 3: North America IV solutions market estimates and forecasts, by type, 2013 - 2024 (USD Million)
  • TABLE 4: North America IV solutions market estimates and forecasts, by nutrient, 2013 - 2024 (USD Million)
  • TABLE 5: U.S. IV solutions market estimates and forecasts, by type, 2013 - 2024 (USD Million)
  • TABLE 6: U.S. IV solutions market estimates and forecasts, by nutrient, 2013 - 2024 (USD Million)
  • TABLE 7: Canada IV solutions market estimates and forecasts, by type, 2013 - 2024 (USD Million)
  • TABLE 8: Canada IV solutions market estimates and forecasts, by nutrient, 2013 - 2024 (USD Million)
  • TABLE 9: Europe IV solutions market estimates and forecasts, by region, 2013 - 2024 (USD Million)
  • TABLE 10: Europe IV solutions market estimates and forecasts, by type, 2013 - 2024 (USD Million)
  • TABLE 11: Europe IV solutions market estimates and forecasts, by nutrient, 2013 - 2024 (USD Million)
  • TABLE 12: UK IV solutions market estimates and forecasts, by type, 2013 - 2024 (USD Million)
  • TABLE 13: UK IV solutions market estimates and forecasts, by nutrient, 2013 - 2024 (USD Million)
  • TABLE 14: Germany IV solutions market estimates and forecasts, by type, 2013 - 2024 (USD Million)
  • TABLE 15: Germany IV solutions market estimates and forecasts, by nutrient, 2013 - 2024 (USD Million)
  • TABLE 16: Asia Pacific IV solutions market estimates and forecasts, by region, 2013 - 2024 (USD Million)
  • TABLE 17: Asia Pacific IV solutions market estimates and forecasts, by type, 2013 - 2024 (USD Million)
  • TABLE 18: Asia Pacific IV solutions market estimates and forecasts, by nutrient, 2013 - 2024 (USD Million)
  • TABLE 19: Japan IV solutions market estimates and forecasts, by type, 2013 - 2024 (USD Million)
  • TABLE 20: Japan IV solutions market estimates and forecasts, by nutrient, 2013 - 2024 (USD Million)
  • TABLE 21: China IV solutions market estimates and forecasts, by type, 2013 - 2024 (USD Million)
  • TABLE 22: China IV solutions market estimates and forecasts, by nutrient, 2013 - 2024 (USD Million)
  • TABLE 23: India IV solutions market estimates and forecasts, by type, 2013 - 2024 (USD Million)
  • TABLE 24: India IV solutions market estimates and forecasts, by nutrient, 2013 - 2024 (USD Million)
  • TABLE 25: Australia IV solutions market estimates and forecasts, by type, 2013 - 2024 (USD Million)
  • TABLE 26: Australia IV solutions market estimates and forecasts, by nutrient, 2013 - 2024 (USD Million)
  • TABLE 27: Latin America IV solutions market estimates and forecasts, by region, 2013 - 2024 (USD Million)
  • TABLE 28: Latin America IV solutions market estimates and forecasts, by type, 2013 - 2024 (USD Million)
  • TABLE 29: Latin America IV solutions market estimates and forecasts, by nutrient, 2013 - 2024 (USD Million)
  • TABLE 30: Brazil IV solutions market estimates and forecasts, by type, 2013 - 2024 (USD Million)
  • TABLE 31: Brazil IV solutions market estimates and forecasts, by nutrient, 2013 - 2024 (USD Million)
  • TABLE 32: Mexico IV solutions market estimates and forecasts, by type, 2013 - 2024 (USD Million)
  • TABLE 33: Mexico IV solutions market estimates and forecasts, by nutrient, 2013 - 2024 (USD Million)
  • TABLE 34: MEA IV solutions market estimates and forecasts, by region, 2013 - 2024 (USD Million)
  • TABLE 35: MEA IV solutions market estimates and forecasts, by type, 2013 - 2024 (USD Million)
  • TABLE 36: MEA IV solutions market estimates and forecasts, by nutrient, 2013 - 2024 (USD Million)
  • TABLE 37: South Africa IV solutions market estimates and forecasts, by type, 2013 - 2024 (USD Million)
  • TABLE 38: South Africa IV solutions market estimates and forecasts, by nutrient, 2013 - 2024 (USD Million)

List of Figures

  • FIG. 1: Market research process
  • FIG. 2: Information procurement
  • FIG. 3: Primary research pattern
  • FIG. 4: IV solutions Market Segmentation
  • FIG. 5: Market Size and Growth Prospects, 2013 - 2024
  • FIG. 6: IV Solutions Market Dynamics
  • FIG. 7: North America geriatric population (Over 60 Years) (Million) (2014 - 2022)
  • FIG. 8: Cancer (all types) incidences per 100,000 populations, 2012
  • FIG. 9: Key Opportunity Prioritized
  • FIG. 10: IV Solutions market - Porter's analysis
  • FIG. 11: IV Solutions market - PESTLE analysis
  • FIG. 12: IV solutions Market Type Outlook Key Takeaways
  • FIG. 13: IV solutions Market Nutrients Outlook Key Takeaways
  • FIG. 14: IV solutions Market: Type Movement Analysis
  • FIG. 15: Global IV solutions market, by type 2013 - 2024 (USD Million)
  • FIG. 16: Global Total Parenteral Nutrition Market (TPN) market, 2013 - 2024 (USD Million)
  • FIG. 17: Global Peripheral Parenteral Nutrition (PPN) market, 2013 - 2024 (USD Million)
  • FIG. 18: IV solutions Market: Nutrient Movement Analysis
  • FIG. 19: Global carbohydrates market, 2013 - 2024 (USD Million)
  • FIG. 20: Global single dose amino acid solution market, 2013 - 2024 (USD Million)
  • FIG. 21: Global vitamins & minerals (salt and electrolyte) market, 2013 - 2024 (USD Million)
  • FIG. 22: Global parenteral lipid emulsion market, 2013 - 2024 (USD Million)
  • FIG. 23: Global others (trace elements) market, 2013 - 2024 (USD Million)
  • FIG. 24: Regional market place: Key takeaways
  • FIG. 25: IV solutions Regional outlook, 2015 & 2024
  • FIG. 26: North America IV solutions market, 2013 - 2024 (USD Million)
  • FIG. 27: U.S. IV solutions market, 2013 - 2024 (USD Million)
  • FIG. 28: Canada IV solutions market, 2013 - 2024 (USD Million)
  • FIG. 29: Europe IV solutions market, 2013 - 2024 (USD Million)
  • FIG. 30: Germany IV solutions market, 2013 - 2024 (USD Million)
  • FIG. 31: UK IV solutions market, 2013 - 2024 (USD Million)
  • FIG. 32: Asia Pacific IV solutions market, 2013 - 2024 (USD Million)
  • FIG. 33: Japan IV solutions market, 2013 - 2024 (USD Million)
  • FIG. 34: China IV solutions market, 2013 - 2024 (USD Million)
  • FIG. 35: India IV solutions market, 2013 - 2024 (USD Million)
  • FIG. 36: Australia IV solutions market, 2013 - 2024 (USD Million)
  • FIG. 37: Latin America IV solutions market, 2013 - 2024 (USD Million)
  • FIG. 38: Brazil IV solutions market, 2013 - 2024 (USD Million)
  • FIG. 39: Mexico IV solutions market, 2013 - 2024 (USD Million
  • FIG. 40: Middle East IV solutions market, 2013 - 2024 (USD Million)
  • FIG. 41: South Africa IV solutions market, 2013 - 2024 (USD Million)
Back to Top